Roth Capital Lowers Earnings Estimates for Gain Therapeutics

Gain Therapeutics, Inc. (NASDAQ:GANX - Free Report) - Roth Capital lowered their Q2 2025 earnings per share (EPS) estimates for shares of Gain Therapeutics in a research note issued on Wednesday, May 14th. Roth Capital analyst B. Pachaiyappan now expects that the company will post earnings per share of ($0.18) for the quarter, down from their previous forecast of ($0.17). The consensus estimate for Gain Therapeutics' current full-year earnings is ($1.00) per share. Roth Capital also issued estimates for Gain Therapeutics' Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.71) EPS, Q1 2026 earnings at ($0.20) EPS, Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.20) EPS, Q4 2026 earnings at ($0.22) EPS and FY2026 earnings at ($0.84) EPS.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.16) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.16).

Several other research analysts have also recently commented on GANX. HC Wainwright reaffirmed a "buy" rating and set a $8.00 target price on shares of Gain Therapeutics in a report on Monday. Scotiabank started coverage on shares of Gain Therapeutics in a report on Friday, March 7th. They set a "sector outperform" rating and a $12.00 target price on the stock. Finally, Chardan Capital reaffirmed a "buy" rating and set a $6.00 target price on shares of Gain Therapeutics in a report on Friday, March 28th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $8.20.

Gain Therapeutics Stock Performance

GANX stock remained flat at $1.81 during mid-day trading on Monday. 86,725 shares of the company's stock traded hands, compared to its average volume of 309,531. Gain Therapeutics has a 1 year low of $0.89 and a 1 year high of $3.19. The business has a fifty day simple moving average of $1.93 and a 200 day simple moving average of $2.00. The firm has a market cap of $53.50 million, a PE ratio of -1.65 and a beta of 0.17. The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.04.

Institutional Trading of Gain Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Sprott Inc. bought a new stake in shares of Gain Therapeutics during the fourth quarter worth $30,000. Benedict Financial Advisors Inc. acquired a new position in shares of Gain Therapeutics during the fourth quarter worth $35,000. Bridgeway Capital Management LLC acquired a new position in shares of Gain Therapeutics during the fourth quarter worth $65,000. Kovitz Investment Group Partners LLC acquired a new position in shares of Gain Therapeutics during the first quarter worth $91,000. Finally, Northern Trust Corp lifted its holdings in shares of Gain Therapeutics by 88.2% during the fourth quarter. Northern Trust Corp now owns 84,586 shares of the company's stock worth $183,000 after purchasing an additional 39,642 shares during the period. Institutional investors own 11.97% of the company's stock.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.